

Tyrosine Protein Kinase JAK2 - Pipeline Review, H1 2020

<https://marketpublishers.com/r/T65A5349EFA7EN.html>

Date: January 2020

Pages: 192

Price: US\$ 3,500.00 (Single User License)

ID: T65A5349EFA7EN

Abstracts

Tyrosine Protein Kinase JAK2 - Pipeline Review, H1 2020

SUMMARY

Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Janus kinase 2 is a non-receptor tyrosine kinase. It is involved in various processes such as cell growth, development, differentiation or histone modifications. It mediates essential signaling events in both innate and adaptive immunity. It plays a pivotal role in signal transduction via its association with type I receptors such as growth hormone, prolactin, leptin, erythropoietin, thrombopoietin or type II receptors including IFN-alpha, IFN-beta, IFN-gamma and multiple interleukins. It plays a role in cell cycle by phosphorylating CDKN1B.

Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) pipeline Target constitutes close to 33 molecules. Out of which approximately 26 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 5, 6, 1, 1, 9 and 2 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 5 and 2 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Dermatology, Respiratory, Ophthalmology, Central Nervous System, Gastrointestinal, Metabolic Disorders, Cardiovascular, Genetic Disorders, Hematological Disorders, Infectious Disease, Musculoskeletal Disorders and Women's Health which include indications Myelofibrosis, Alopecia Areata, Atopic Dermatitis (Atopic Eczema), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), Acute Myelocytic Leukemia

(AML, Acute Myeloblastic Leukemia), Asthma, Graft Versus Host Disease (GVHD), Rheumatoid Arthritis, Chronic Myelomonocytic Leukemia (CMML), Diabetic Macular Edema, Glioblastoma Multiforme (GBM), Myeloproliferative Disorders, Primary Myelofibrosis, Psoriasis, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Aicardi-Goutieres Syndrome (AGS), Anaplastic Astrocytoma, Anterior Uveitis, Auto Inflammatory Disease, Autoimmune Disorders, B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia), Breast Hyperplasia, Bronchiolitis Obliterans, Chronic Cutaneous Lupus Erythematosus (CCLE)/Discoid Lupus Erythematosus (DLE), Chronic Lymphocytic Leukemia (CLL), Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Crohn's Disease (Regional Enteritis), Dermatitis (Eczema), Dermatomyositis, Diffuse Large B-Cell Lymphoma, Epstein-Barr Virus (HHV-4) Infections, Essential Thrombocythemia, Gastrointestinal Tract Cancer, Giant Cell Arteritis (Temporal Arteritis/Cranial Arteritis/Horton Disease), Glaucoma, Gliosarcoma, Head And Neck Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Hematological Tumor, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Hypereosinophilic Syndrome, Hypopharyngeal Cancer, Inflammation, Inflammatory Bowel Disease, Juvenile Arthritis, Laryngeal Cancer, Leukemia, Lung Transplant Rejection, Metastatic Prostate Cancer, Myelodysplastic Syndrome, Oral Cavity (Mouth) Cancer, Oropharyngeal Cancer, Parkinson's Disease, Pediatric Diffuse Intrinsic Pontine Glioma, Peripheral T-Cell Lymphomas (PTCL), Polycythemia Vera, Polymyalgia Rheumatica (PMR), Primary Biliary Cholangitis (Primary Biliary Cirrhosis), Proliferative Diabetic Retinopathy (PDR), Refractory Acute Myeloid Leukemia, Refractory Multiple Myeloma, Relapsed Acute Myeloid Leukemia, Relapsed Multiple Myeloma, Solid Tumor, Systemic Idiopathic Juvenile Arthritis, Systemic Lupus Erythematosus, Systemic Sclerosis (Scleroderma), Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease), Thrombocythemia Myelofibrosis, Triple-Negative Breast Cancer (TNBC), Ulcerative Colitis, Vitiligo and Wet (Neovascular/Exudative) Macular Degeneration.

The latest report Tyrosine Protein Kinase JAK2 - Pipeline Review, H1 2020, outlays comprehensive information on the Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-

specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2)

The report reviews Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects

The report assesses Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to

formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Overview

Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Therapeutics
Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Therapeutics
Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Companies
Involved in Therapeutics Development

Adastra Pharmaceuticals Inc

Aerie Pharmaceuticals Inc

AstraZeneca Plc

Bristol-Myers Squibb Co

Celon Pharma SA

CJ HealthCare Corp

Concert Pharmaceuticals Inc

CTI BioPharma Corp

Eli Lilly and Co

Hangzhou East China Pharmaceutical Group Co Ltd

Incyte Corp

Japan Tobacco Inc

Merck & Co Inc

Novartis AG

NS Pharma Inc

OHM Oncology

Pfizer Inc

Sierra Oncology Inc

Simcere Pharmaceutical Group

Suzhou Zelgen Biopharmaceutical Co Ltd

Theravance Biopharma Inc

Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Drug Profiles

AR-13503 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AZD-1480 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

baricitinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CHZ-868 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CJ-15314 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CPL-407105 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CTP-543 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

delgocitinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fedratinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FLLL-12 - Drug Profile

Product Description
Mechanism Of Action
R&D Progress
jaktinib hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MA-2014 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
mometinib dihydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NS-018 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OB-756 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OHM-581 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pacritinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ruxolitinib phosphate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SAR-317461 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress

Small Molecule to Inhibit AURKA, EGFR and JAK2 for Gastrointestinal Tract Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit JAK1, JAK2 and TYK2 for Diabetic Macular Edema - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit JAK1, JAK2, JAK3 and TYK2 for Asthma - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit JAK1, JAK2, JAK3 and TYK2 for Rheumatoid Arthritis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit JAK2 for Leukemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit JAKs for Lung Transplant Rejection - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit JAK1, JAK2, JAK3 and TYK2 for Dermatology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit JAK2 and FLT3 for Myelofibrosis and Acute Myeloid Leukemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit JAK2 and JAK3 for Immunology and Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit JAK2 for Myeloproliferative Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit JAK 1 and JAK 2 for Inflammation - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TD-1473 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TD-8236 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

zotiraciclib citrate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Dormant Products

Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Discontinued Products

Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) - Product Development Milestones

Featured News & Press Releases

Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2020

Number of Products under Development by Therapy Areas, H1 2020

Number of Products under Development by Indications, H1 2020

Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020

Number of Products under Development by Indications, H1 2020 (Contd..2), H1 2020

Number of Products under Development by Indications, H1 2020 (Contd..3), H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..1)

Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Products under Development by Companies, H1 2020 (Contd..2), H1 2020

Products under Development by Companies, H1 2020 (Contd..3), H1 2020

Products under Development by Companies, H1 2020 (Contd..4), H1 2020

Products under Development by Companies, H1 2020 (Contd..5), H1 2020

Number of Products under Investigation by Universities/Institutes, H1 2020

Products under Investigation by Universities/Institutes, H1 2020

Number of Products by Stage and Mechanism of Actions, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Pipeline by Aadastra Pharmaceuticals Inc, H1 2020

Pipeline by Aerie Pharmaceuticals Inc, H1 2020

Pipeline by AstraZeneca Plc, H1 2020

Pipeline by Bristol-Myers Squibb Co, H1 2020

Pipeline by Celon Pharma SA, H1 2020

Pipeline by CJ HealthCare Corp, H1 2020

Pipeline by Concert Pharmaceuticals Inc, H1 2020

Pipeline by CTI BioPharma Corp, H1 2020

Pipeline by Eli Lilly and Co, H1 2020

Pipeline by Hangzhou East China Pharmaceutical Group Co Ltd, H1 2020

Pipeline by Incyte Corp, H1 2020

Pipeline by Japan Tobacco Inc, H1 2020

Pipeline by Merck & Co Inc, H1 2020

Pipeline by Novartis AG, H1 2020

Pipeline by NS Pharma Inc, H1 2020

Pipeline by OHM Oncology, H1 2020

Pipeline by Pfizer Inc, H1 2020
Pipeline by Sierra Oncology Inc, H1 2020
Pipeline by Simcere Pharmaceutical Group, H1 2020
Pipeline by Suzhou Zelgen Biopharmaceutical Co Ltd, H1 2020
Pipeline by Theravance Biopharma Inc, H1 2020
Dormant Products, H1 2020
Dormant Products, H1 2020 (Contd..1), H1 2020
Dormant Products, H1 2020 (Contd..2), H1 2020
Dormant Products, H1 2020 (Contd..3), H1 2020
Dormant Products, H1 2020 (Contd..4), H1 2020
Dormant Products, H1 2020 (Contd..5), H1 2020
Discontinued Products, H1 2020
Discontinued Products, H1 2020 (Contd..1), H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2020

Number of Products under Development by Therapy Areas, H1 2020

Number of Products under Development by Top 10 Indications, H1 2020

Number of Products by Stage and Mechanism of Actions, H1 2020

Number of Products by Routes of Administration, H1 2020

Number of Products by Stage and Routes of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

COMPANIES MENTIONED

Adastral Pharmaceuticals Inc

Aerie Pharmaceuticals Inc

AstraZeneca Plc

Bristol-Myers Squibb Co

Celon Pharma SA

CJ HealthCare Corp

Concert Pharmaceuticals Inc

CTI BioPharma Corp

Eli Lilly and Co

Hangzhou East China Pharmaceutical Group Co Ltd

Incyte Corp

Japan Tobacco Inc

Merck & Co Inc

Novartis AG

NS Pharma Inc

OHM Oncology

Pfizer Inc

Sierra Oncology Inc

Sincere Pharmaceutical Group

Suzhou Zelgen Biopharmaceutical Co Ltd

Theravance Biopharma Inc

I would like to order

Product name: Tyrosine Protein Kinase JAK2 - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/T65A5349EFA7EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/T65A5349EFA7EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970